Pharmaceutical News News 3 December 2025

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.

23 January 2026

Biotechnology·NYSE:GILD·NYSE:JNJ·NYSE:MRK·Pharmaceutical News·Stock Market

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.

16 January 2026

Biotechnology·NASDAQ:IBRX·Pharmaceutical News·Stock Market

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.

12 January 2026

NASDAQ:SRPT·Pharmaceutical News

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Soleno Therapeutics shares fell 5.6% to $42.95 Friday, underperforming the biotech sector after law firms announced “investigations” tied to past short-seller claims about Vykat XR. The company reported $66 million in quarterly revenue from the drug, approved for Prader-Willi syndrome, with 1,043 patient start forms since March. The stock hovered just above its 52-week low. Next update expected late February.

9 January 2026

NASDAQ:SLNO·Pharmaceutical News·Stock Market

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology shares surged 25.1% to $52.45 after the company advanced the expected release of late-stage bladder cancer trial results to the first half of 2026. The PIVOT-006 Phase 3 trial enrolled over 360 patients and compares cretostimogene grenadenorepvec to surveillance after tumor removal. Trading volume topped 4.1 million shares by midday. Morgan Stanley raised its price target on the stock to $89.

9 January 2026

Biotechnology·NASDAQ:CGOI·Pharmaceutical News·Stock Market

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering shares surged 24% to $8.33 premarket after reporting 64% overall 12-month survival in a 34-patient Phase 2a pancreatic cancer trial. The company compared this to a 35% benchmark from standard chemotherapy. Median progression-free survival reached 8.5 months. Immuneering plans a larger data update and to start a Phase 3 trial in mid-2026.

8 January 2026

Biotechnology·NASDAQ:IMRX·Pharmaceutical News·Stock Market

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.

6 January 2026

NASDAQ:ZBIO·Pharmaceutical News·Stock Market

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.

30 December 2025

Biotechnology·NASDAQ:PRAX·Pharmaceutical News·Stock Market

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.

26 December 2025

Biotechnology·NASDAQ:EWTX·Pharmaceutical News·Stock Market

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.

24 December 2025

Biotechnology·NYSE:LLY·Pharmaceutical News·Stock Market

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences said Monday it will license Assembly Biosciences’ investigational herpes simplex virus programs, including two oral candidates, for a $35 million payment. The move expands Gilead’s antiviral pipeline days after it joined a Trump administration drug-pricing deal. Shares traded around $123–$124, slightly lower on the day. No new HSV therapies have been approved in the U.S. or Europe for over 25 years.

22 December 2025

NASDAQ:GILD·Pharmaceutical News

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme (Abivax SA) stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index (NBI) becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A (mergers and acquisitions) story. What’s happening with ABIVAX stock today (December 22, 2025) Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be

22 December 2025

Mergers and Acquisitions·Pharmaceutical News

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

NEW YORK — December 12, 2025 — Applied Therapeutics, Inc. (NASDAQ: APLT) is in the spotlight after announcing a definitive agreement to be acquired by Cycle Group Holdings Limited (“Cycle”), a rare-disease-focused company that operates as Cycle Pharmaceuticals. The headline terms include a small upfront cash payment and a potentially meaningful (but uncertain) contingent value right (CVR) tied to future FDA approvals and sales milestones—setting up a high-volatility, event-driven setup for APLT stock as the market digests what’s “real” value versus what’s optionality. GlobeNewswire Below is a detailed roundup of what’s new as of 12/12/2025, why APLT stock moved, and

12 December 2025

Biotechnology·NASDAQ:APLT·Pharmaceutical News·Stock Market

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading.Exicure+2Investing.com+2 Below is a comprehensive look at the latest trial results, recent financials, analyst and algorithmic forecasts, and the key risks around Exicure stock as of December 9, 2025. Exicure (XCUR) Stock Today: Price, Volume and Recent Performance Exicure shares have been extraordinarily volatile going into

9 December 2025

NASDAQ:XCUR·Pharmaceutical News·Stock Market

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering. With the next U.S. trading session set to open on Tuesday, December 9, investors are trying to decide whether this is the beginning of a new obesity heavyweight—or a classic biotech spike that could retrace just as fast. Below is a concise, news-style wrap of everything that happened after the bell on December 8 and what

9 December 2025

NASDAQ:WVE·Pharmaceutical News·Stock Market

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing

8 December 2025

NASDAQ:ARWR·Pharmaceutical News

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ: TNXP) has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule into major depressive disorder (MDD), and watched its stock price explode more than 10,000% over the last year. Tonix Pharmaceuticals Holding Corp.+2Fintel+2 As of the latest close on Friday, 5 December 2025, TNXP stock finished at $19.64, up 0.56% on the day, with after‑hours trading nudging it to $19.80. Over the past week, the share price jumped about 23%, and

7 December 2025

NASDAQ:TNXP·Pharmaceutical News·Stock Market

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1 As of Friday, December 5, Biomea Fusion shares were trading in the low‑$1 range, giving the company a market

5 December 2025

NASDAQ:BMEA·Pharmaceutical News·Stock Market

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis At the same time, investors are weighing sizable legal risks and an approaching patent cliff — making BMY one of the more eventful large‑cap healthcare stocks to watch into 2026. Below is a comprehensive, SEO‑friendly rundown of today’s Bristol-Myers Squibb stock news, forecasts, and analysis as of December 3, 2025. BMY Stock Price

3 December 2025

Artificial Intelligence·Biotechnology·Pharmaceutical News·Stock Market

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

As of December 2, 2025, CVS Health Corporation (NYSE: CVS) finds itself in a classic “good news, bad headlines” moment: the stock has pulled back after a strong 2025 rally, the company agreed to a federal settlement over insulin-pen billing, and yet Wall Street’s forecasts still point to further upside. Below is a structured rundown of the latest price action, news, forecasts and analyses as of and since December 2, 2025. Share price on December 2, 2025: dip after a big year On Tuesday, December 2, 2025, CVS Health shares fell about 1.9%, closing at $77.62, even as the broader